Ulf Henrik Mellqvist

Summary

Affiliation: Sahlgrenska University Hospital
Country: Sweden

Publications

  1. ncbi Cyclophosphamide plus dexamethasone is an efficient initial treatment before high-dose melphalan and autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of a randomized comparison with vincristine, doxorubicin,
    Ulf Henrik Mellqvist
    Department of Hematology, Sahlgrenska University Hospital, Gothenburg, Sweden
    Cancer 112:129-35. 2008
  2. pmc Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial
    Ulf Henrik Mellqvist
    Department of Medicine, Section of Hematology and Coagulation, Sahlgrenska University Hospital, Gothenburg, Sweden
    Blood 121:4647-54. 2013
  3. ncbi Intensive therapy for multiple myeloma in patients younger than 60 years. Long-term results focusing on the effect of the degree of response on survival and relapse pattern after transplantation
    Stig Lenhoff
    Department of Hematology, University Hospital, S 221 85 Lund, Sweden
    Haematologica 91:1228-33. 2006
  4. doi Melphalan 100 mg/m2 with stem cell support as first relapse treatment is safe and effective for myeloma patients with long remission after autologous stem cell transplantation
    Cecilie Blimark
    Section of Hematology and Coagulation, Department of Internal Medicine, Sahlgrenska University Hospital, University of Gothenburg, Gothenburg, Sweden
    Eur J Haematol 87:117-22. 2011
  5. ncbi Impact of age on survival after intensive therapy for multiple myeloma: a population-based study by the Nordic Myeloma Study Group
    Stig Lenhoff
    Lund University Hospital, Lund, Sweden
    Br J Haematol 133:389-96. 2006
  6. ncbi [CPP (Cost Per Patient) is functioning well in the everyday care. The myeloma care program in Vastra Gotaland--an illustrative example]
    Dick Stockelberg
    Sektionen för hematologi och koagulation, Medicinkliniken, Sahlgrenska Universitetssjukhuset, Goteborg
    Lakartidningen 100:3316-8. 2003
  7. pmc Deep vein thrombosis after monoclonal gammopathy of undetermined significance and multiple myeloma
    Sigurdur Y Kristinsson
    Department of Medicine, Division of Hematology, Karolinska University Hospital and Institutet, Stockholm, Sweden
    Blood 112:3582-6. 2008

Collaborators

Detail Information

Publications7

  1. ncbi Cyclophosphamide plus dexamethasone is an efficient initial treatment before high-dose melphalan and autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of a randomized comparison with vincristine, doxorubicin,
    Ulf Henrik Mellqvist
    Department of Hematology, Sahlgrenska University Hospital, Gothenburg, Sweden
    Cancer 112:129-35. 2008
    ..This randomized trial, which was initiated in 2001 by the Nordic Myeloma Study Group, was an attempt to bring a larger portion of patients to ASCT more quickly...
  2. pmc Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial
    Ulf Henrik Mellqvist
    Department of Medicine, Section of Hematology and Coagulation, Sahlgrenska University Hospital, Gothenburg, Sweden
    Blood 121:4647-54. 2013
    ..Consolidation with bortezomib after ASCT in bortezomib-naive patients improves PFS without interfering with QOL. This trial was registered at www.clinicaltrials.gov as #NCT00417911...
  3. ncbi Intensive therapy for multiple myeloma in patients younger than 60 years. Long-term results focusing on the effect of the degree of response on survival and relapse pattern after transplantation
    Stig Lenhoff
    Department of Hematology, University Hospital, S 221 85 Lund, Sweden
    Haematologica 91:1228-33. 2006
    ..Long-term results are presented, including the impact of the degree of response on survival and relapse pattern after transplantation...
  4. doi Melphalan 100 mg/m2 with stem cell support as first relapse treatment is safe and effective for myeloma patients with long remission after autologous stem cell transplantation
    Cecilie Blimark
    Section of Hematology and Coagulation, Department of Internal Medicine, Sahlgrenska University Hospital, University of Gothenburg, Gothenburg, Sweden
    Eur J Haematol 87:117-22. 2011
    ..As the goal for the treatment for relapsed myeloma should be disease control while maintaining quality of life, lower doses of melphalan might be preferable...
  5. ncbi Impact of age on survival after intensive therapy for multiple myeloma: a population-based study by the Nordic Myeloma Study Group
    Stig Lenhoff
    Lund University Hospital, Lund, Sweden
    Br J Haematol 133:389-96. 2006
    ..Our results indicate that intensive therapy prolongs survival also at age 60-64 years but with less superiority than in younger patients...
  6. ncbi [CPP (Cost Per Patient) is functioning well in the everyday care. The myeloma care program in Vastra Gotaland--an illustrative example]
    Dick Stockelberg
    Sektionen för hematologi och koagulation, Medicinkliniken, Sahlgrenska Universitetssjukhuset, Goteborg
    Lakartidningen 100:3316-8. 2003
  7. pmc Deep vein thrombosis after monoclonal gammopathy of undetermined significance and multiple myeloma
    Sigurdur Y Kristinsson
    Department of Medicine, Division of Hematology, Karolinska University Hospital and Institutet, Stockholm, Sweden
    Blood 112:3582-6. 2008
    ..5%) that progressed to MM, only one person had a DVT diagnosis before transformation. Our findings suggest the operation of shared underlying mechanisms causing coagulation abnormalities among patients with MGUS and MM...